| « Previous month | Next month » |
SGS has officially launched a new auditing service designed to alleviate the quality, regulatory and safety issues in pharmaceutical supply chains, which are increasingly extending across the globe.
DSM Pharmaceuticals now has its new commercial scale cytotoxic contract manufacturing facility up and running, and is only the second company in the US to offer such a service on this scale.
Pharmaceutical manufacturers, distributors and retailers alike have welcomed a unanimous vote by the California State Board of Pharmacy to delay for another two years the implementation of electronic pedigree requirements for tracking drugs from the manufacturer through to the pharmacy.
China's drug regulatory authority is finally responding to curb its damaged reputation by urging its local authorities to take a more proactive role in stemming what is fast becoming a global heparin contamination, sparked by material sourced in the country.
1200 sales representatives are the latest casualties of Wyeth's recently announced cost cutting drive, which strives to eliminate 10 per cent of the work force - 5,000 jobs - over the next three years.
France, Italy, and Denmark are the latest countries to recall heparin products as the contamination scare spreads over materials linked to China.
The pharmaceutical industry in the UK faces tougher legislation on the disclosure of adverse events in clinical trials following the MHRA's thwarted attempt to prosecute GlaxoSmithKline for allegedly withholding information about risks of suicidal behaviour in children and adolescents taking its antidepressant Seroxat (paroxetine).
BioConvergence has forged a 'significant' supply chain partnership with Eli Lilly, worth millions of dollars over ten years.
France, Italy, and Denmark are the latest countries to recall heparin products as the contamination scare spreads over materials linked to China.
Eden Biodesign, Archimica and Hikal have all recently announced new contract manufacturing news.
BioReliance has established itself in the Asia Pacific with the opening of its first office in the region, in Tokyo, Japan.
The pharmaceutical industry has lost confidence in the UK as a place to do business to an "alarming degree" and the situation is only set to deteriorate, reveals new research.
India's Nicholas Piramal has announced several business moves of late, designed to enhance its position on the world stage.
Outsourcing-Pharma.com compiles the news that has featured in the clinical contract community of late, involving PRA International and Premier Research.
International drug trials on children are monitoring safety at levels that are "unacceptable," according to a new analysis.
Cambrex Corp, the US-based manufacturer of small-molecule active pharmaceutical ingredients (APIs) and advanced intermediates for the drug industry, has announced that one of its customers is recalling a product for which Cambrex currently supplies the API.
Outsourcing-Pharma compiles the latest in motley pharma services news, including PRA International, Odyssey Logistics and Kuehne+Nagel.
Pfizer has indicated that it is planning to increase its activity in India as it searches for new revenue streams and operating efficiencies.
The heparin recall has widened after a lot of heparin sodium USP active pharmaceutical ingredient (API) produced by Scientific Protein Laboratories (SPL) was found to contain a heparin-like contaminant.
Genomic services firm Expression Analysis has purchased the first-ever commercially-available technology to allow the sequencing of a single molecule of DNA, without amplification.
The US Food and Drug Administration (FDA) has now identified the contaminant found in samples of Baxter's recalled heparin and confirmed that it is indeed linked to a Chinese manufacturing plant.
Microarray expert Affymetrix has started outsourcing some of its jobs in the US to Singapore.
Outsourcing-Pharma.com compiles the news that has featured in the clinical contract community of late, involving Phlexglobal, The Smithers Group, Veeda Clinical Research and Trial Care International.
Switzerland's Siegfried Holding says that a significant jump in 2007 net profit, up 54 per cent to CHF 49.7m ($50m), vindicates its decision to refocus on the active pharmaceutical ingredients and generics sector.
Mid-sized European pharma company Nycomed has struck a deal to offshore the vast majority of its raw materials sourcing to India, in a move which could affect around 200 jobs.
inVentiv Clinical has become the latest contract research organisation (CRO) to open up shop in blossoming Latin America in a bid to gain more of a global reach.
Applied Biosystems has sequenced a human genome for just $60,000 in a project that significantly undercuts the $100,000 milestone achieved by the industry and setting the scene for a price war between DNA sequencing tool specialists.
Outsourcing-Pharma tracks the latest eClinical movements, featuring Medidata Solutions, Phase Forward and Datatrak.
Despite the challenges that emerging market present, such as intellectual property (IP) exposure and drug pricing controls, the pharma industry is not being deterred.
The US Food and Drug Administration (FDA) has alerted the media that it has taken a significant step forward in its plans to establish a presence on the ground in China.
Israeli generics maker Teva will spend $100m to double its manufacturing capacity in Hungary, as the pharma global spread continues.
In this week's review of activity within the preclinical research services arena, news has emerged involving Evotec, Dr Reddy's and GlaxoSmithKline (GSK).
European healthcare logistics provider Alloga has expanded its territory into Greece and Cyprus.
Outsourcing-Pharma explores the driving force behind the pharma industry's escalating wandering eye towards emerging markets.
Pharmaceutics International has been branching out of late, with an expansion, an acquisition and a new partnership.
The costs of introducing any formal good manufacturing practice (GMP) requirements for potentially high-risk pharmaceutical excipients in the European Union would far exceed the likely benefits, concludes an impact assessment for the European Commission.
Outsourcing-Pharma.com compiles the news that has featured in the clinical contract community of late, involving Quintiles, AbCRO, China Gate and Micro Therapeutic Research Labs.
Cognizant is gaining ground in the life sciences arena, this week inking a $95m data management deal with AstraZeneca, just three months after sealing another multi-million dollar deal with Merck & Co.
Eli Lilly has again teamed up with Indian research firm Suven Life Sciences in a deal that will focus on preclinical research of molecules in the therapeutic area of central nervous system (CNS) disorders.
Jaycare has risen from the ashes of administration after being bought by a competitor, Cope Allman Plastic Packaging.
Germany's Merck KGaA is still on the lookout for acquisitions or in-licensing deals to fill out its pharmaceutical business following the purchase and integration of Swiss biotech Serono.
Patheon's first quarter results have continued to be impacted by its underperforming Puerto Rico operations, although restructuring plans to remedy the situation are in full swing.
Cobra Biomanufacturing, Crucell, Vetter, Arch Pharmalabs and Lonza have all recently announced new contract manufacturing news.
DNA sequencing services provider GATC Biotech has announced the opening of a new subsidiary in Stockholm, Sweden, as it widens the net in Europe.
The CEO of Californian company Nektar Therapeutics says that 2007 has been key in transforming the company into a fully integrated drug development organisation, despite the setback with Pfizer's inhaled insulin product Exubera.
The prospects for a viable market in inhaled insulin therapies were looking markedly thinner this week after Eli Lilly pulled the plug on its joint development programme with drug delivery specialist Alkermes for AIR Insulin.
The made-in-China heparin scare has now spread beyond the US, with Germany and Japan both recalling the drug.
The promise of genuine returns on investment, facilitated by plummeting hardware costs, will fuel a dramatic growth surge in the US market for radio frequency identification (RFID) technology in pharmaceutical manufacturing and distribution over the next five years, a new report predicts.
Patheon, Keller Crescent, Bilcare and Molecular Profiles have all had people on the move in the world of pharmaceutical outsourcing.
Portugal's Hovione has become the latest in a spate of pharma industry players to invest further in China.
Galapagos has watched its loss widen over the past year as it stepped up its internal research and development activities.
A US Food and Drug Administration (FDA) investigation into the recent Baxter heparin scare has uncovered a contaminant in the product that was sourcing the active pharmaceutical ingredient (API) from a Chinese manufacturer.
Pfizer has outlined a number of strategies for growing its fledgling pipeline and lowering its cost base and is planning to increase globalisation and accelerate growth in emerging markets as part of this.
Pharmanet watched its profits drop in the fourth quarter of 2007 after being hurt by higher costs.
In this week's review of activity within the preclinical research services arena, news has emerged involving Althea Technologies, Tepnel and BioFocus DPI.
UK-based AstraZeneca has recently given the region's dominant telecommunications provider, British Telecom (BT) a greater role in its business, to the tune of £25m.
The US Food and Drug Administration (FDA) has alerted the media to the preliminary findings of its inspection of the Chinese facility that supplied the active pharmaceutical ingredient (API) for Baxter's heparin - now recalled from the market after a safety scare.
Outsourcing-Pharma.com compiles the news that has featured in the clinical contract community of late, involving Pharmatech, Entelos, Kendle and ClinfoSource.
Innovative pharma firms should take a closer look at pharmacogenomics in order to move away from the current 'one-size-fits-all approach' to drug development, according to an industry expert.
The globalisation of the supply chain increasingly challenges the US Food and Drug Administration's ability to ensure the quality of pharmaceuticals on the US market, acknowledges the acting director of the agency's Center for Drug Evaluation and Research.
Asia has been dubbed the "land of golden opportunities" by PricewaterhouseCoopers (PWC), who says it is poised to become the largest pharmaceutical consumer and producer in the world.
Big pharma's thirst for external innovation is set to persist amidst the blockbuster drought.
Kendle has reported a profit for the fourth quarter of 2007, a turn around from the situation this time last year when the company was losing money.
2008 will be a year for both challenges and opportunities in outsourcing, according to Indian IT and business process outsourcing (BPO) services advisory firm Tholons.
A UK chemicals plant has become the latest casualty of GlaxoSmithKline's (GSK's) pledge to make the business leaner with the help of outsourcing and offshoring.
| « Previous month | Next month » |